Suloctidil

A peripheral vasodilator that was formerly used in the management of peripheral and cerebral vascular disorders. It is hepatotoxic and fatalities have occurred. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1312)

Also Known As:

CP-556S; Suloctidil Hydrochloride; Benzenemethanol, 4-((1-methylethyl)thio)-alpha-(1-(octylamino)ethyl)-, (R*,S*)-

Networked: 46 relevant articles (3 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Amino Alcohols: 20
    - Propanolamines: 4
      - Suloctidil: 46
        tipropidil
  - Ethylamines: 5
    - Phenethylamines: 28
      - Suloctidil: 46
        tipropidil
- Alcohols: 595
  - Amino Alcohols: 20
    - Propanolamines: 4
      - Suloctidil: 46
        tipropidil
  - Propanols: 3
    - Propanolamines: 4
      - Suloctidil: 46
        tipropidil

Experts

1.	Li, Yafeng: 1 article (01/2022)
2.	Qing, Jianbo: 1 article (01/2022)
3.	Samuel, Sonia Biju: 1 article (01/2022)
4.	Song, Wenzhu: 1 article (01/2022)
5.	Tian, Lingling: 1 article (01/2022)
6.	Banyard, Jacqueline: 1 article (01/2020)
7.	Barrows, Courtney: 1 article (01/2020)
8.	Basu, Sudipta: 1 article (01/2020)
9.	Bielenberg, Diane R: 1 article (01/2020)
10.	Chung, Ivy: 1 article (01/2020)

Related Diseases

1.	Dementia (Dementias) 01/01/1987 - "An experimental evaluation of the efficacy of suloctidil in the treatment of primary degenerative dementia." 08/01/1988 - "Suloctidil is a new drug that is currently being evaluated in many clinical trials for use in dementia and thrombotic disorders. " 01/01/1987 - "A double-blind, placebo-controlled randomized design was employed to test the efficacy and optimal dosage of Suloctidil in the treatment of primary degenerative dementia (PDD i.e., Alzheimer's disease). " 01/01/1998 - "The type of CNS effects produced by EGb (as established by HZI's CEEG psychotropic drug database) in elderly dementia patients were similar to those induced by tacrine responders as well as those seen after the administration of other "cognitive activators" (pramiracetam, vinpocetine, BMY-21502, suloctidil, and lisuride) and anti-dementia drugs approved in the United States or Europe (tacrine, donepezil, nimodipine, piracetam, and oxiracetam) from our database. "
2.	Cognitive Dysfunction 01/01/1985 - "However, further analysis of the results showed that in the sub-group of patients with moderate mental deterioration on entry, suloctidil treatment produced significant improvement from baseline in the Rey 15 words test and the results were significantly different from those in patients with severe mental deterioration. " 01/01/1985 - "A double-blind, parallel group, placebo-controlled study was carried out in 30 elderly patients with moderate to severe mental deterioration to assess the effect of suloctidil on their mental condition. " 01/01/1985 - "Double-blind trial of suloctidil versus placebo in moderate to severe mental deterioration."
3.	Pain (Aches) 03/01/1981 - "By contrast, when the analysis was limited to legs with claudication pain, a significant improvement occurred only in the suloctidil-treated group. " 03/01/1981 - "These findings suggest that suloctidil may improve the claudication symptoms of patients with chronic arterial obstructive disease and in particular the perfusion of legs experiencing claudication pain. "
4.	Intermittent Claudication 01/01/1982 - "In a recent double-blind trial lasting over 6 months, 40 patients suffering from intermittent claudication were randomly allocated to receive 300 mg of suloctidil per day or exactly matching placebo capsules. " 01/01/1982 - "A double-blind trial of suloctidil v. placebo in intermittent claudication." 03/01/1981 - "Controlled trial of suloctidil in intermittent claudication." 01/01/1984 - "Intermittent claudication: Suloctidil v.s. " 01/01/1976 - "Medical treatment of intermittent claudication: a comparative double-blind study of suloctidil, dihydroergotoxine and placebo."
5.	Hepatitis 10/01/1985 - "[Hepatitis caused by suloctidil]." 03/01/1985 - "[Fulminating hepatitis due to suloctidil]." 11/01/1984 - "[Hepatitis from suloctidil (Fluvisco)]." 10/06/1984 - "[Suloctidil hepatitis: bringing into focus]." 06/01/1984 - "[Another cirrhogenic hepatitis from suloctidil (Fluvisco)]."

Related Drugs and Biologics

1.	Ticlopidine (Ticlid)
2.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)
3.	Dipyridamole (Persantine)
4.	Sulfinpyrazone (Anturane)
5.	Aspirin (Acetylsalicylic Acid)
6.	Aspartate Aminotransferases (Aspartate Transaminase)
7.	Alanine Transaminase (SGPT)
8.	Therapeutic Uses
9.	Nimodipine (Modus)
10.	Flunarizine

Related Therapies and Procedures

1.	Secondary Prevention
2.	Therapeutics
3.	Artificial Heart (Artificial Hearts)
4.	Drug Therapy (Chemotherapy)